[A23-141] Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V
Last updated 20.06.2024
Project no.:
A23-141
Commission:
Commission awarded on 21.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with previously untreated diffuse large B-cell lymphoma
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A23-141_en
| Project no. | Title | Status |
|---|---|---|
| G20-01 | Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G22-22 | Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A23-140 | Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-60 | Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141 | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.